Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
52.66
+0.25 (0.48%)
At close: Jul 19, 2024, 4:00 PM
52.76
+0.10 (0.19%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for CRNX stock have an average target of 65.33, with a low estimate of 48 and a high estimate of 97. The average target predicts an increase of 24.06% from the current stock price of 52.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRNX stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $47 → $54 | Buy | Maintains | $47 → $54 | +2.54% | Jul 9, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $97 | Buy | Maintains | $97 | +84.20% | Jul 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +13.94% | Jun 28, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $80 | Buy | Reiterates | $80 | +51.92% | Jun 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $55 → $74 | Buy | Maintains | $55 → $74 | +40.52% | Jun 4, 2024 |
Financial Forecast
Revenue This Year
2.13M
from 4.01M
Decreased by -46.87%
Revenue Next Year
14.42M
from 2.13M
Increased by 576.22%
EPS This Year
-3.62
from -3.69
EPS Next Year
-3.89
from -3.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.9M | 60.9M | 126.0M | 283.1M | 739.5M |
| Avg | 2.1M | 14.4M | 50.2M | 177.7M | 412.6M |
| Low | 588,000 | 2.9M | 26.8M | 104.8M | 223.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 46.5% | 2,756.5% | 773.9% | 463.5% | 316.2% |
| Avg | -46.9% | 576.2% | 248.4% | 253.7% | 132.2% |
| Low | -85.3% | 37.9% | 85.6% | 108.6% | 25.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.35 | -3.09 | -2.37 | -0.81 | 0.78 |
| Avg | -3.62 | -3.89 | -3.82 | -2.34 | -0.07 |
| Low | -4.17 | -4.96 | -4.84 | -3.14 | -1.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.